Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 and Radiation in Rectal Cancer
NCT03297710Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trifluridine + tipiracil in rectal cancer, sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Dec 2017; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03297710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297710.